FDA Pathway Could Make Bespoke CRISPR Therapies Viable

Around 350 million people globally live with one of the 5,000 genetic diseases, many of which are caused by mutations unique to a single individual. Under current rules, each personalised CRISPR therapy – distinguished by its guide RNA sequence – is classified as a new drug, requiring its own clinical trial and costing upwards of US$25 million and four years to reach approval.

The FDA's proposed 'plausible mechanism pathway' would enable the enrollment of multiple patients with different mutations but shared clinical presentations in a single trial. Only the first gene editor in such a trial would require the full battery of preclinical studies; subsequent editors, differing only in guide RNA sequence, would need far less supporting data. The authors estimate this could reduce the time to treatment to as little as three months at under $250,000 per patient.

Beyond regulatory reform, they call for four structural changes: dedicated FDA review capacity with patient-family engagement; mandatory data sharing across development programmes; investment in domestic supply chains and outcome-linked payment models coordinated between the FDA and the Centers for Medicare and Medicaid Services; and international regulatory harmonisation, with self-contained 'mini-factory' platforms enabling deployment beyond elite academic centres.

The commentary is authored by Fyodor D. Urnov (University of California, Berkeley, and Innovative Genomics Institute) and Sadik H. Kassim (Danaher, Boston). It was published in Nature on 21 April 2026.